Anixa Biosciences Inc (NASDAQ:ANIX) Receives Average Recommendation of “Hold” from Brokerages

Anixa Biosciences Inc (NASDAQ:ANIX) has earned a consensus recommendation of “Hold” from the five research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $8.50.

A number of research firms recently issued reports on ANIX. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday. Wall Street Zen lowered Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research note on Friday. Finally, D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, April 8th.

Insiders Place Their Bets

In other Anixa Biosciences news, CEO Amit Kumar bought 21,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were acquired at an average cost of $2.50 per share, for a total transaction of $52,500.00. Following the purchase, the chief executive officer directly owned 630,812 shares of the company’s stock, valued at $1,577,030. The trade was a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 26.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Anixa Biosciences

Institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC bought a new position in Anixa Biosciences in the 2nd quarter worth about $33,000. Northwestern Mutual Wealth Management Co. increased its stake in Anixa Biosciences by 2,000.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares during the last quarter. Cetera Investment Advisers bought a new position in Anixa Biosciences in the 4th quarter worth about $35,000. Benjamin Edwards Inc. bought a new position in Anixa Biosciences in the 2nd quarter worth about $37,000. Finally, Marshall Wace LLP bought a new position in Anixa Biosciences in the 2nd quarter worth about $39,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $2.61 on Friday. Anixa Biosciences has a 52-week low of $2.32 and a 52-week high of $5.46. The firm has a market cap of $88.79 million, a price-to-earnings ratio of -8.42 and a beta of 0.59. The business’s fifty day moving average is $2.78 and its 200 day moving average is $3.06.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Equities analysts predict that Anixa Biosciences will post -0.31 EPS for the current fiscal year.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.